Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Physician Response to Implementation of Genotype-Tailored Antiplatelet Therapy
-
Published Date:
Feb 17 2016
-
Publisher's site:
-
Source:Clin Pharmacol Ther. 100(1):67-74.
-
[PDF-255.38 KB]
Details:
-
Alternative Title:Clin Pharmacol Ther
-
Personal Author:
-
Description:Physician responses to genomic information are vital to the success of precision medicine initiatives. We prospectively studied a pharmacogenomics implementation program for the propensity of clinicians to select antiplatelet therapy based on CYP2C19 loss-of-function variants in stented patients. Among 2,676 patients, 514 (19.2%) were found to have a CYP2C19 variant affecting clopidogrel metabolism. For the majority (93.6%) of the cohort, cardiologists received active and direct notification of CYP2C19 status. Over 12 months, 57.6% of poor metabolizers and 33.2% of intermediate metabolizers received alternatives to clopidogrel. CYP2C19 variant status was the most influential factor impacting the prescribing decision (hazard ratio [HR] in poor metabolizers 8.1, 95% confidence interval [CI] [5.4, 12.2] and HR 5.0, 95% CI [4.0, 6.3] in intermediate metabolizers), followed by patient age and type of stent implanted. We conclude that cardiologists tailored antiplatelet therapy for a minority of patients with a CYP2C19 variant and considered both genomic and nongenomic risks in their clinical decision-making.
-
Subject:
-
Pubmed ID:26693963
-
Pubmed Central ID:PMC4899238
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
image/gif 
image/jpeg 
application/vnd.openxmlformats-officedocument.wordprocessingml.document
application/octet-stream 
image/gif 
image/jpeg 
image/gif 
image/jpeg 
image/gif 
image/jpeg
No Related Documents.
Email
CDC-INFO
